• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Late mortality rates ‘inadvertently reversed’ in 5-year study of paclitaxel-eluting stent

February 21, 2019 By Sarah Faulkner

Cook Medical - updated logoThe journal Circulation said this week that the all-cause mortality rates in a study comparing a paclitaxel stent and percutaneous transluminal angioplasty in people with peripheral artery disease were “inadvertently reversed” by the authors.

In the first version of the paper, originally published in 2016, researchers reported that the 5-year all-cause mortality rate for people treated with Cook Medical‘s Zilver PTX stent was 10.2% and 16.9% for the PTA group. But the correction reversed those numbers.

“We understand this is upsetting and we know that we made an error. We’ve corrected it. The numbers in one sentence of the article were transposed and an incorrect diagram was used. We welcome collaborative, transparent conversations about long-term patient outcomes,” Cook Medical wrote on Twitter.

Also this month, Medtronic (NYSE:MDT) reported that it inadvertently omitted mortality data for patients treated with its In.Pact Admiral paclitaxel-coated balloon in two analyses.

The data troubles for paclitaxel devices come as researchers are trying to better understand the long-term safety of paclitaxel-coated and paclitaxel-eluting devices. Earlier this year, a meta-analysis published in the Journal of the American Heart Association suggested that patients treated with paclitaxel devices for PAD could be at a higher risk for late death compared to people treated with uncoated devices.

Device-makers like Medtronic and Boston Scientific (NYSE:BSX) have stood behind the use of their paclitaxel products in PAD patients in the wake of these reports.

The FDA wrote a letter to healthcare providers after the meta-analysis was published in JAHA, saying that the “benefits continue to outweigh the risks for approved paclitaxel-coated balloons and paclitaxel-eluting stents when used in accordance with their indications for use.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: Boston Scientific, cook medical, Medtronic

IN CASE YOU MISSED IT

  • BD stock up on Street-beating preliminary quarterly revenue numbers
  • Locate Bio lands FDA breakthrough nod for bone infection device
  • PerkinElmer to acquire Oxford Immunotec
  • Evonik buys polymers business from Durect Corp.
  • New Croatian notified body designated to European MDR

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS